Detalhe da pesquisa
1.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
2.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
3.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
4.
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
J Natl Compr Canc Netw
; : 1-8, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38744314
5.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
6.
The emerging role of PI3K inhibitors for solid tumour treatment and beyond.
Br J Cancer
; 128(12): 2150-2162, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36914722
7.
The multispeciality approach to the management of localised kidney cancer.
Lancet
; 400(10351): 523-534, 2022 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35868329
8.
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Oncologist
; 28(3): e167-e170, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576430
9.
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
Oncologist
; 28(1): 72-79, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124890
10.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
11.
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
Curr Oncol Rep
; 25(11): 1247-1258, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37773078
12.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489363
13.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(7): 888-898, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688173
14.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
15.
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases.
Br J Cancer
; 126(3): 419-429, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272498
16.
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Oncologist
; 27(12): 1048-1057, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36146944
17.
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
J Transl Med
; 20(1): 371, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35974365
18.
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology.
J Transl Med
; 20(1): 593, 2022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36514092
19.
Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy.
Cytometry A
; 101(7): 597-605, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507402
20.
Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice.
BMC Cancer
; 22(1): 754, 2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820816